Phase II/III Study of Nab-Paclitaxel and Gemcitabine with or without SBP-101 in Patients with Metastatic Pancreatic Cancer
The purpose of this phase II/III study is to evaluate the safety and efficacy of nab-paclitaxel and gemcitabine with or without SBP-101 in patients with untreated metastatic pancreatic adenocarcinoma.
Study ID: CL-SPB-101-04
Trial Phase: Phase II/III
Trial Sponsor: Panbela Therapeutics, Inc.
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, SBP-101